Pharvaris (PHVS) Other Non Operating Income (2020 - 2026)
Pharvaris' (PHVS) quarterly Other Non Operating Income came in at -$6.6 million in Q2 2025, down 335.69% YoY from $2.8 million in Q2 2024, and down 335.69% on a QoQ basis from $2.8 million in Q2 2024.
Pharvaris (PHVS) Other Non Operating Income (2020 - 2026) Analysis & Trends
Pharvaris (PHVS) has 6 years of Other Non Operating Income data on file, last reported at -$6.6 million in Q2 2025.
- Quarterly Other Non Operating Income fell 335.69% year-over-year to -$6.6 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was -$3.2 million (down 120.36% YoY) and the FY2025 annual result came in at -$11.6 million, down 235.98% from the prior year.
- Other Non Operating Income eased to -$6.6 million in Q2 2025, from $2.8 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $12.3 million in Q2 2022 to a low of -$6.6 million in Q2 2025.
- A 5-year average of $2.7 million and a median of $3.3 million in 2024 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 20896.33% in 2021, down 13639.54% in 2021.
- Tracing PHVS's Other Non Operating Income over 5 years: stood at $4.8 million in 2021, then jumped by 158.56% to $12.3 million in 2022, then tumbled by 94.09% to $727085.7 in 2023, then jumped by 287.56% to $2.8 million in 2024, then tumbled by 335.69% to -$6.6 million in 2025.
- The last three Other Non Operating Income figures came in at -$6.6 million (Q2 2025), $2.8 million (Q2 2024), and $727085.7 (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Pharvaris | 2.29 Bn | 1.92 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.37 Mn |
| Jun 30, 2025 | -6.64 Mn |
| Jun 30, 2024 | 2.82 Mn |
| Jun 30, 2023 | 727,085.71 |
| Mar 31, 2023 | -108,636.15 |
| Jun 30, 2022 | 12.31 Mn |
| Mar 31, 2022 | 3.81 Mn |
| Dec 31, 2021 | 4.76 Mn |
| Sep 30, 2021 | 5.17 Mn |
| Jun 30, 2021 | -2.98 Mn |
| Mar 31, 2021 | 7.02 Mn |
| Dec 31, 2020 | -938,431.07 |
| Sep 30, 2020 | -147,572.54 |
| Jun 30, 2020 | -21,688.85 |
| Mar 31, 2020 | -33,750.73 |